Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single-Center Experience.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long-acting monoclonal antibody approved in 2023, offers single-dose seasonal protection. We conducted a single-center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024-2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non-recipients, including one RSV-related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.